Active	Status	Sponsor type	Region	Phase	Filter
5 Active 3 Inactive 8 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « March » « 2025 » M T W T F S S 24 25 26 27 28 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 6   - « March » « 2025 » M T W T F S S 24 25 26 27 28 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 6   Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
solrikitug (MK-8226) / Uniquity Bio
RAINIER, NCT06496607: A Study to Evaluate Solriktug in Adult Participants With Asthma	Recruiting	2	84	US	Biological: Solrikitug Low Dose, Biological: Solrikitug Mid Dose, Biological: Solrikitug High Dose, Placebo	Uniquity One (UNI), DevPro Biopharma	Asthma	04/25	08/25
ZION, NCT06496620: A Study to Evaluate Solrikitug in Participants With COPD	Recruiting	2	171	US	Biological: Solrikitug low dose, Biological: Solrikitug high dose, Placebo	Uniquity One (UNI), DevPro Biopharma	COPD	04/25	08/25
NCT06598462: A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults with Eosinophilic Esophagitis	Recruiting	2	157	US, RoW	Solrikitug Low Dose, Solrikitug Mid Dose, Solrikitug High Dose, Placebo	Uniquity One (UNI)	Eosinophilic Esophagitis (EoE)	04/27	08/27
NCT06640920: A Study to Investigate Efficacy and Safety of NSI-8226 in Healthy Participants	Active, not recruiting	1	48	US	Cohort A, Cohort B, Cohort C, Cohort D	Uniquity One (UNI)	Healthy	10/24	10/24
NCT06868082: A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Solrikitug in Healthy Japanese and Non-Japanese Participants	Not yet recruiting	1	32	RoW	Solrikitug	Uniquity One (UNI)	Healthy	08/25	12/25

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
solrikitug (MK-8226) / Uniquity Bio
RAINIER, NCT06496607: A Study to Evaluate Solriktug in Adult Participants With Asthma	Recruiting	2	84	US	Biological: Solrikitug Low Dose, Biological: Solrikitug Mid Dose, Biological: Solrikitug High Dose, Placebo	Uniquity One (UNI), DevPro Biopharma	Asthma	04/25	08/25
ZION, NCT06496620: A Study to Evaluate Solrikitug in Participants With COPD	Recruiting	2	171	US	Biological: Solrikitug low dose, Biological: Solrikitug high dose, Placebo	Uniquity One (UNI), DevPro Biopharma	COPD	04/25	08/25
NCT06598462: A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults with Eosinophilic Esophagitis	Recruiting	2	157	US, RoW	Solrikitug Low Dose, Solrikitug Mid Dose, Solrikitug High Dose, Placebo	Uniquity One (UNI)	Eosinophilic Esophagitis (EoE)	04/27	08/27
NCT06640920: A Study to Investigate Efficacy and Safety of NSI-8226 in Healthy Participants	Active, not recruiting	1	48	US	Cohort A, Cohort B, Cohort C, Cohort D	Uniquity One (UNI)	Healthy	10/24	10/24
NCT06868082: A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Solrikitug in Healthy Japanese and Non-Japanese Participants	Not yet recruiting	1	32	RoW	Solrikitug	Uniquity One (UNI)	Healthy	08/25	12/25